Search
Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigational[A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616] … [A189165] JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity for JAK1 aims to improve the safety profile of filgotinib while maintaining clinical efficacy
Azlocillin
go.drugbank.com/drugs/DB01061ApprovedAzlocillin is a semisynthetic ampicillin-derived acylureido penicillin.
VidPrevtyn Beta
go.drugbank.com/drugs/DB16427ApprovedVidPrevtyn Beta is an adjuvanted, recombinant COVID-19 vaccine developed collaboratively by GlaxoSmithKline (GSK) and Sanofi Pasteur. … [L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from
Synonyms: SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain)Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational, and are switched to camizestrant while continuing the same CDK4/6 inhibitor. … Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally
Coagulation factor VII human
go.drugbank.com/drugs/DB13150ApprovedInvestigationalCoagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETSARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
go.drugbank.com/drugs/DB18705Approved[L48902] It is intended to elicit protection against Omicron XBB.1.5, one of the dominant circulating SARS-CoV-2 subvariants in 2023. … [A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market.
Levobupivacaine
go.drugbank.com/drugs/DB01002ApprovedInvestigationalWithdrawnLevobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. … Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine.
Ziftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigational[A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory … [L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells.
Synonyms: Menin-mll interaction inhibitor ko 539Polyethylene glycol 300
go.drugbank.com/drugs/DB11161ApprovedLow molecular weight glycols are observed to exhibit antibacterial properties as well. PEG 300 is found in eye drops as a lubricant to temporarily relieve redness, burning and irritation of the eyes. … Polyethylene glycols are widely used in biochemistry, structural biology, and medicine in addition to pharmaceutical and chemical industries.
Mipomersen
go.drugbank.com/drugs/DB05528ApprovedDue to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program. … Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.